Regulation of PCSK9 by nutraceuticals

Amir Abbas Momtazi, Maciej Banach, Matteo Pirro, Niki Katsiki, Amirhossein Sahebkar

Research output: Contribution to journalReview article

56 Citations (Scopus)

Abstract

PCSK9 (proprotein convertase subtilisin kexin type 9) is a liver secretory enzyme that regulates plasma low-density lipoprotein (LDL) cholesterol (LDL-C) levels through modulation of LDL receptor (LDLR) density on the surface of hepatocytes. Inhibition of PCSK9 using monoclonal antibodies can efficiently lower plasma LDL-C, non-high-density lipoprotein cholesterol and lipoprotein (a). PCSK9 inhibition is also an effective adjunct to statin therapy; however, the cost-effectiveness of currently available PCSK9 inhibitors is under question. Nutraceuticals offer a safe and cost-effective option for PCSK9 inhibition. Several nutraceuticals have been reported to modulate PCSK9 levels and exert LDL-lowering activity. Mechanistically, those nutraceuticals that inhibit PCSK9 through a SREBP (sterol-responsive element binding protein)-independent pathway can be more effective in lowering plasma LDL-C levels compared with those inhibiting PCSK9 through the SREBP pathway. The present review aims to collect available data on the nutraceuticals with PCSK9-inhibitory effect and the underlying mechanisms.

Original languageEnglish
Pages (from-to)157-169
Number of pages13
JournalPharmacological Research
Volume120
DOIs
Publication statusPublished - 1 Jun 2017

Fingerprint Dive into the research topics of 'Regulation of PCSK9 by nutraceuticals'. Together they form a unique fingerprint.

Cite this